Abstract
Imatinib mesylate is an effective, small-molecule, selective tyrosine kinase inhibitor, which inhibits BCR-ABL in patients with chronic myeloid leukemia, c-kit in patients with gastrointestinal tumor (GIST), and platelet-derived growth factors in hypereosinophilic syndrome. Above all, bone marrow necrosis is a rare complication of imatinib usage. If newly developed increased opacity bone lesions are seen in patients with metastatic GIST, it is usual to consider those lesions as bone metastasis. Also, it is true that making a differential diagnosis between bone marrow change (bone marrow necrosis) and disease progression (bone metastasis) is both clinically and radiologically difficult. Because it may alter treatment options according to early distinguish bone metastasis and imatinib related-bone necrosis, a bone biopsy is recommended. Here, we report a case that a biopsy confirmed bone marrow necrosis due to imatinib, even though investigations such as magnetic resonance imaging, and whole-body bone scan indicated more favor to the metastatic lesion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
